Defendant

Smith & Nephew Inc.

1 case as defendant.

Cases
1
Active
0
1 closed
Filed
—
Top venue
D Mass
1 case

Company profile

Smith & Nephew Inc. is the principal U.S. operating subsidiary of Smith & Nephew plc (LSE: SN; NYSE: SNN), a UK-headquartered portfolio medical technology group. The plc was founded in Hull, England, in 1856 and is headquartered in Watford, Hertfordshire, England. The U.S. entity is a Delaware corporation with its principal place of business at 1450 Brooks Road, Memphis, Tennessee. The group is public, a FTSE 100 constituent, with roughly 17,349 employees (FY2024) and reported revenue of $5,810 million in FY2024. It is not majority-owned by any parent.

Operations: Smith+Nephew develops, manufactures and sells medical devices across three global business units — Orthopaedics (hip, knee and shoulder implants, robotics-assisted and digital enabling technology such as the CORI Surgical System, and trauma/extremity products), Sports Medicine & ENT (soft-tissue repair instruments, arthroscopic enabling technologies and ENT products), and Advanced Wound Management (wound dressings, bioactives and negative-pressure wound therapy devices). FY2024 revenue split roughly 40% Orthopaedics, 31% Sports Medicine & ENT and 29% Advanced Wound Management; the U.S. accounts for about half of sales. It operates in approximately 100 countries.

Patent-litigation posture: An operating company being attacked, not an NPE. In the tracked data it appears only as a defendant (1 case) and never as a plaintiff (0 cases), which is consistent with a large device maker defending its commercial products rather than asserting a licensed portfolio. The single tracked matter sits in the District of Massachusetts, not a plaintiff-friendly venue like the Eastern District of Texas.

Notable case: ConforMIS, Inc. v. Smith & Nephew Inc., No. 1:16-cv-10420 (D. Mass., filed Feb. 2016). ConforMIS alleged that Smith & Nephew's VISIONAIRE patient-specific cutting guides, used with off-the-shelf JOURNEY II, LEGION and GENESIS II knee implants, infringed eight patents covering patient-specific instrumentation. Smith & Nephew filed numerous inter partes reviews at the PTAB and the district case was stayed pending IPR. The parties settled in September 2018, with Smith & Nephew paying $10.5 million and entering a limited patent cross-license. Note that individual patent-litigation outcomes are not reflected in the case counts above.

ConforMIS, Inc. v. Smith & Nephew Inc.

settled
Docket:
1:16-cv-10420
Court:
D. Mass.
Patents:8556983

ConforMIS sued Smith & Nephew in the District of Massachusetts. Litigation was stayed in April 2017 pending 16 IPRs; PTAB held several patents unpatentable, and the case settled in September 2018. Narrative states the '983 patent was not identified as asserted in this case.